Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Cytokine induction in human PBMCs

PS Pottayil G. Sasikumar
NS Naremaddepalli S. Sudarshan
SA Srinivas Adurthi
RR Raghuveer K. Ramachandra
DS Dodderi S. Samiulla
AL Anirudha Lakshminarasimhan
AR Anuradha Ramanathan
TC Talapaneni Chandrasekhar
AD Amit A. Dhudashiya
ST Sumalatha R. Talapati
NG Nagesh Gowda
SP Sreenivasulareddy Palakolanu
JM Jiju Mani
BS Bandi Srinivasrao
DJ David Joseph
NK Nigam Kumar
RN Rashmi Nair
HA Hanudatta S. Atreya
NG Nagaraj Gowda
MR Murali Ramachandra
ask Ask a question
Favorite

To determine the potential for any unforeseen T-cell agonist activity in humans, a study was conducted where human PBMCs from healthy donors were pre-cultured either at normal density (2 × 105 cells/well) or at high density (1 × 107 cells/mL) in vitro to increase cell–cell contacts and immune scanning as described24 and then treated with CA-170 (10 nM to 1000 nM) IL-2, TNF-α and IFN-γ cytokine release was measured in the culture supernatants at 24 and 48 h. Human PBMCs stimulated with anti-CD3 alone or anti-CD3 + anti-CD28 antibodies served as positive controls for cytokine release in this assay.

Copyright and License information: The Author(s) ©2021
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A